- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05885464
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Medical Information
- Phone Number: 857-327-8641
- Email: clinicalinfo@beamtx.com
Study Locations
-
-
California
-
Stanford, California, United States, 94304
- Recruiting
- Stanford University School of Medicine
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Blood Cancer Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- Recruiting
- The University of Kansas Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Cleveland Clinic- Taussig Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon- TriStar Bone Marrow Transplant
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- Methodist Hospital - Texas Transplant Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Ages 18 to ≤ 50 years.
- Ages ≥ 1 year to < 18 years, after health authority approval.
T-ALL/T-LL that is CD7-positive (defined as at least 20% of blasts positive for CD7 by flow cytometry or immunohistochemistry based on assessment of the study site's CLIA [Clinical Laboratory Improvement Amendments of 1988] certified facility) in second or greater relapse, first relapse post-transplant relapse, or chemotherapy-refractory disease. Specifically:
Second or greater relapse or post-transplant relapse, defined as:
- BM with ≥ 5% lymphoblasts by morphologic assessment or evidence of extramedullary disease at screening after second documented CR; OR
- Flow cytometric confirmation of relapsed T-ALL of at least 0.1% after second CR documented to have been MRD negative < 0.1%; OR
- Any detectable relapsed disease post-allogeneic HSCT with flow cytometric confirmation of T-ALL of at least 0.1%; OR
- Biopsy confirmed evidence of relapsed T-LL on lymph node biopsy after second CR; OR
- Any detectable disease post-allogeneic transplant with biopsy confirmed evidence of T-LL on lymph node biopsy
Refractory disease, defined as:
- Primary refractory T-ALL or T-LL, defined as failure to achieve CR after induction chemotherapy, per investigator assessment and based on biopsy-confirmed evidence of residual T-ALL or T-LL; OR
- Relapsed, refractory disease, defined as > 5% BM blasts or biopsy-confirmed evidence of residual TLL after 1 course of re-induction chemotherapy for patients who have relapsed after previously achieving a CR NOTE: Patients with mixed phenotype acute leukemia with T-cell dominant phenotype may be enrolled if the aforementioned criteria are met.
- Eligible for myeloablative conditioning for and allogeneic HSCT based on the investigator's assessment with an available donor identified by a FACT accredited transplant center.
Key Exclusion Criteria:
- CNS involvement meeting any of the following criteria: CNS-3 disease, progressive CNS involvement despite therapy, CNS parenchymal or cranial nerve lesions on imaging.
- Clinically active CNS dysfunction or known history of irreversible neurological toxicity related to prior antileukemic therapy.
- Receipt of prior CD7 targeted therapy.
- Systemic antileukemic therapy intended to induce or maintain remission within 14 days prior to completion of screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fludarabine, cyclophosphamide and alemtuzumab
Lymphodepletion regimen including fludarabine, cyclophosphamide and alemtuzumab
|
A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
|
Experimental: Fludarabine, cyclophosphamide without alemtuzumab
Lymphodepletion regimen without Alz but consisting of the same dose of Flu/Cy as in the other arm
|
A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only)
Time Frame: Through study completion, an average of 25 months
|
Through study completion, an average of 25 months
|
Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusion
Time Frame: From treatment with BEAM-201 through study completion
|
From treatment with BEAM-201 through study completion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients who achieve MRD negative response (defined as < 0.1%) by flow cytometry or next generation sequencing (NGS) in patients achieving morphologic response
Time Frame: Starting at Day 28 and multiple time points up to Month 24
|
Starting at Day 28 and multiple time points up to Month 24
|
Proportion of patients treated with BEAM-201 deemed appropriate for HSCT based on investigator assessment of clinical response
Time Frame: Through study completion, an average of 25 months
|
Through study completion, an average of 25 months
|
Duration of Response (DOR)
Time Frame: Through study completion, an average of 25 months
|
Through study completion, an average of 25 months
|
Relapse-free survival (RFS)
Time Frame: Through study completion, an average of 25 months
|
Through study completion, an average of 25 months
|
Overall survival
Time Frame: Through study completion, an average of 25 months
|
Through study completion, an average of 25 months
|
Relapse-related mortality
Time Frame: Through study completion, an average of 25 months
|
Through study completion, an average of 25 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Lymphoma
- Leukemia
- Lymphoma, Non-Hodgkin
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Other Study ID Numbers
- BTX-ALO-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoblastic Lymphoma
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...United States
-
Mehrdad Abedi, MDAmgenCompletedStage IV Adult Lymphoblastic Lymphoma | Contiguous Stage II Adult Lymphoblastic Lymphoma | Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Stage I Adult Lymphoblastic Lymphoma | Stage III Adult Lymphoblastic Lymphoma | Untreated Adult Acute Lymphoblastic LeukemiaUnited States
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...Netherlands
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryNetherlands
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryNetherlands
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryNetherlands
-
National Cancer Institute (NCI)Active, not recruitingAdult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditionsUnited States, Canada, Australia, New Zealand
-
Children's Hospital Medical Center, CincinnatiTerminatedRecurrent Adult Lymphoblastic Lymphoma | Refractory Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma | Relapsed Lymphoblastic LeukemiaUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); The Leukemia...TerminatedT-Acute Lymphoblastic Leukemia | Adult T Lymphoblastic LymphomaUnited States
-
First Affiliated Hospital of Zhejiang UniversityRecruitingCytarabine+Thiotepa + Fludarabine + Busulfan | T Cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaChina
Clinical Trials on BEAM-201
-
QurAlis CorporationRecruitingAmyotrophic Lateral SclerosisCanada, Germany, Netherlands, Ireland, United Kingdom, Belgium
-
Modulation Therapeutics, Inc.H. Lee Moffitt Cancer Center and Research InstituteRecruitingUveal Melanoma | MetastaticUnited States
-
Royal Prince Alfred Hospital, Sydney, AustraliaCompleted
-
TWi Biotechnology, Inc.CompletedType 2 Diabetes MellitusUnited States, Taiwan
-
Suzhou Connect Biopharmaceuticals, Ltd.Active, not recruiting
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompleted
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPsoriasisGermany, Israel, Poland, Spain
-
Tonix Pharmaceuticals, Inc.CompletedTension-Type HeadacheUnited States
-
PegBio Co., Ltd.CompletedType2 Diabetes MellitusChina
-
Southwest Regional Wound Care CenterCompleted